Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Nicorette "still in its infancy in many significant countries" such as Germany, Italy, Spain, where sales not yet on par with smaller Ireland market, VP-Global Specialty Operations Stephen MacMillan tells investors Nov. 29. Sales are up 28% for first nine months of 2001, spurred by new global marketing campaign, reacquisition of brand from Canadian distributor and recent OTC switch in Japan, where sales are $1 mil. per week. MacMillan also heralded 8.5% sales increase for Pharmacia's global consumer healthcare - about triple the industry average - and 13% sales growth in North America...

Related Content

Nicorette International Growth Integral To Pfizer OTC Strength – Hassan
Nicorette Global Sales Jump 62% In Q4 With International Expansion





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts